Skip to content

Ginkgo Bioworks DNA Free cash flow

Free cash flow at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$816M+126%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$37.35M-68.3%
Azenta logo
AzentaAZTA
$6.11M-12.7%
Regenxbio logo
RegenxbioRGNX
-$77.42M-337%
Charles River Laboratories logo
Charles River LaboratoriesCRL
TEC
Bio-TechneTECH

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Calculated from Ginkgo Bioworks’s reported figures.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's free cash flow?
Ginkgo Bioworks (DNA) reported free cash flow of -$48.62M in Q1 2026.
How has Ginkgo Bioworks's free cash flow changed year-over-year?
Ginkgo Bioworks's free cash flow increased by 17.8% year-over-year, from -$59.14M to -$48.62M.
What is the long-term trend for Ginkgo Bioworks's free cash flow?
Over 4 years (2021 to 2025), Ginkgo Bioworks's free cash flow has grown at a -12.9% compound annual growth rate (CAGR), from -$310.34M to -$178.72M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.